ULTRASOUND AND INTEGRAL DOPPLER MARKERS OF PLACENTAL DYSFUNCTION IN PREGNANT WOMEN WITH CHRONIC HCV INFECTION

Authors:

Abstract:

The results of studying ultrasound and Dopplerometric features of the fetoplacental complex in pregnant women with chronic HCV infection are presented and their relationship with biochemical parameters of liver function is evaluated. The study included 69 pregnant women, including 44 patients with chronic HCV infection (the main group), 25 women with a physiological course of pregnancy (the control group). The groups were comparable in age, gestation period, and body mass index (p>0.05). In pregnant women with chronic HCV infection, a statistically significant increase in liver transaminase activity was detected, the thickness of the placenta was significantly less than in the control group (p=0.048), premature maturation of the placenta (p<0.001) was detected. Calcifications and placental cysts were detected more frequently in patients with HCV infection (p<0.001 and p=0.054, respectively). There was an increase in the pulsation index of the uterine arteries and umbilical cord artery in pregnant women with HCV infection (p<0.05); and a decrease in the cerebroplacental (p=0.016) and cerebroplacental-uterine ratios (p<0.001). Comprehensive ultrasound evaluation of the placenta and Dopplerometric examination of blood flow in the mother-placenta-fetus system may be recommended for early detection of placental dysfunction in pregnant women with chronic HCV infection.

Keywords:

pregnant women hepatitis C ultrasound Dopplerometry mother-placenta-fetus system

References:

1. Zapopadna Yu.M. Funktsionalnyy stan fetoplatsentarnoho kompleksu u vahitnykh z HCV-infektsiyeyu. Ukrainian Journal of Perinatology and Pediatrics. 2023; 3(95): 35-42. DOI: 10.15574/PP.2023.95.35. [in Ukrainian]
2. Abbasi F, Almukhtar M, Fazlollahpour-Naghibi A, Alizadeh F, Behzad Moghadam K, Jafari Tadi M, et al. Hepatitis C infection seroprevalence in pregnant women worldwide: a systematic review and meta-analysis. EClinical Medicine. 2023; 66: 102327. DOI: 10.1016/j.eclinm.2023.102327.
3. Dhurvey V, Satoskar PR. Association of Cerebroplacental Ratio by Colour Doppler with Perinatal Outcome in Near Term and Term Foetuses. J Obstet Gynaecol India. 2023;73(Suppl 1):103-107. doi: 10.1007/s13224-023-01823-2.
4. Dutra K, Fenkel J. Hepatitis C treatment during pregnancy: time for a practice change. American Journal of Obstetrics & Gynecology MFM, 2026; 8(2):101865
5. El-Shabrawi MHF, Kamal NM, Mogahed EA, Elhusseini MA, Aljabri MF. Perinatal transmission of hepatitis C virus: an update. Arch Med Sci. 2020; 16(6): 1360-1369. DOI: 10.5114/aoms.2019.83644.
6. Ferreira J, Caldeira J, Bicho M, Faustino P, Serejo F. Hepatitis C Virus: An Overview of Its Chronic Impact on Liver Function, Metabolic Dysregulation, Inflammatory–Oxidative Pathogenesis and Epigenetic Memory. International Journal of Molecular Sciences. 2026; 27(8): 3559. DOI: 10.3390/ijms27083559.
7. Graupner O, Meister M, Lecker L, Karim-Payab S, Franz C, Carow J, et al. Role of the cerebro-placental-uterine ratio in predicting adverse perinatal outcome in low-risk pregnancies at term. Arch Gynecol Obstet. 2023; 308: 849-55. DOI: 10.1007/s00404-022-06733-8.
8. He S, Shuang G, Yinglan W, Lan W, Wey W, Ailing W, et al. Prevalence and factors associated with hepatitis C among pregnant women in China: a cross-sectional study. Sci Rep. 2023;13:759. DOI: 10.1038/s41598-023-27668-3.
9. Hong J, Kumar S. Circulating biomarkers associated with placental dysfunction and their utility for predicting fetal growth restriction. Clinical Science.2023; 137(8):579-595. DOI:10.1042/CS20220300
10. Khanjani S, Farahbod F, Zarean E, Tarrahi MJ, Mohammadi B. Evaluation of the relation between cerebroplacental ratio, umbilical-cerebral ratio, and cerebroplacental-uterine ratio with the occurrence of adverse perinatal outcomes in pregnancies complicated by fetal growth restriction. Immunopathol Persa. 2023; 9(2): e39503. DOI:10.34172/ipp.2023.39503.
11. MacDonald TM, Hui L, Robinson AJ, Dane KM, Middleton AL, Tong S, et al. Cerebral-placental-uterine ratio as novel predictor of late fetal growth restriction: prospective cohort study. Ultrasound Obstet Gynecol. 2019; 54: 367-75. DOI: 10.1002/uog.20150.
12. Martin-Alonso R, Rolle V, Akolekar R, de Paco Matallana C, Fernández-Buhigas I, Sánchez-Camps MI, et al. Efficiency of the Cerebroplacental Ratio in Identifying High-Risk Late-Term Pregnancies. Medicina. 2023; 59(9): 1670. DOI: 10.3390/medicina59091670.
13. Meler E, Martínez J, Boada D, Mazarico E, Figueras F. Doppler studies of placental function. Placenta. 2021;108:91-96. DOI: 10.1016/j.placenta.2021.03.014.
14. Novillo-Del Álamo B, Martínez-Varea A, Satorres-Pérez E, Nieto-Tous M, Bello-Martínez de Velasco S, García-Florenciano MV, et al. Cerebroplacental Ratio as a Predictive Factor of Emergency Cesarean Sections for Intrapartum Fetal Compromise: A Systematic Review. J Clin Med. 2024;13(6):1724. DOI: 10.3390/jcm13061724.
15. Pan CQ, Zhu BS, Xu JP, Li JX, Sun LJ, Tian HX, et al. Pregnancy and fetal outcomes of chronic hepatitis C mothers with viremia in China. World J Gastroenterol. 2022;28(34):5023-5035. DOI: 10.3748/wjg.v28.i34.5023.
16. Raj R, Ranjan R, Majumdar P, Chakraborty S. Observational Study on the Role of Doppler Ultrasound in Assessing Placental Insufficiency in High-Risk Pregnancies. European Journal Cardiovascular Medicine. 2023; 1493); 1204 – 1212.
17. Rios J, Alpert L, Mehra S, Schmidt N, Kushner T. Overview of Hepatitis C in Pregnancy: Screening, Management, and Treatment. Journal of the Pediatric Infectious Diseases Society. 2024; 13(5): S171–S178. DOI: 10.1093/jpids/piae070.
18. Shen G.-F, Ge C.-H, Shen W, Liu Y.-H, Huang X.-Y. Association between hepatitis C infection during pregnancy with maternal and neonatal outcomes: a systematic review and meta-analysis. European Review for Medical and Pharmacologica Sciences. 2023; 27: 3475-3488.
19. Sheridan MA, Zhou J, Franz AWE, Schust DJ. Modeling the Human Placenta to Investigate Viral Infections During Pregnancy. Frontiers in Virology. 2022; 2: 831754. DOI: 10.3389/fviro.2022.831754.
20. WHO Efforts to eliminate hepatitis delivers gains but more action needed to meet 2030 targets. Q28 April 2026. Bangkok/Geneva. https://www.who.int/news/item/28-04-2026-efforts-to-eliminate-hepatitis-delivers-gains-but-more-action-needed-to-meet-2030-targets.

Publication:

«World of Medicine and Biology» Vol. 22 No. 97 (2026), pp. 58-63
UDC 618.36-002:616.36-002.2-073.43

DOI:

https://doi.org/10.26724/2079-8334-2026-3-97-58-63